CN100569235C - 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 - Google Patents

用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 Download PDF

Info

Publication number
CN100569235C
CN100569235C CNB200580004060XA CN200580004060A CN100569235C CN 100569235 C CN100569235 C CN 100569235C CN B200580004060X A CNB200580004060X A CN B200580004060XA CN 200580004060 A CN200580004060 A CN 200580004060A CN 100569235 C CN100569235 C CN 100569235C
Authority
CN
China
Prior art keywords
pharmaceutical composition
physiology
asthma
acceptable salt
glycopyrronium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200580004060XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1913883A (zh
Inventor
J·格德
J·毛斯
P·J·克诺塔
I·塞莱尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Meda Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma GmbH and Co KG filed Critical Meda Pharma GmbH and Co KG
Publication of CN1913883A publication Critical patent/CN1913883A/zh
Application granted granted Critical
Publication of CN100569235C publication Critical patent/CN100569235C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB200580004060XA 2004-02-06 2005-01-24 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合 Expired - Fee Related CN100569235C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195604P 2004-02-06 2004-02-06
US60/541,956 2004-02-06

Publications (2)

Publication Number Publication Date
CN1913883A CN1913883A (zh) 2007-02-14
CN100569235C true CN100569235C (zh) 2009-12-16

Family

ID=34837533

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200580004060XA Expired - Fee Related CN100569235C (zh) 2004-02-06 2005-01-24 用于哮喘和copd长期治疗的抗胆碱能药和糖皮质激素的组合

Country Status (16)

Country Link
US (2) US20050175548A1 (enExample)
EP (1) EP1713473B1 (enExample)
JP (1) JP4819699B2 (enExample)
CN (1) CN100569235C (enExample)
AU (1) AU2005210085B2 (enExample)
CA (1) CA2551780C (enExample)
DK (1) DK1713473T3 (enExample)
ES (1) ES2413011T3 (enExample)
HR (1) HRP20130460T1 (enExample)
NO (1) NO336882B1 (enExample)
NZ (1) NZ548300A (enExample)
PL (1) PL1713473T3 (enExample)
PT (1) PT1713473E (enExample)
RU (1) RU2440813C2 (enExample)
SI (1) SI1713473T1 (enExample)
WO (1) WO2005074918A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PL1971369T3 (pl) * 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
HRP20140582T4 (hr) 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2881182C (en) * 2012-08-09 2021-01-26 Chase Pharmaceuticals Corporation Piperidinium quaternary salts
NZ710740A (en) 2013-02-28 2020-06-26 Dermira Inc Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
AU2014375301C1 (en) 2013-12-30 2026-02-19 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2016149756A1 (en) * 2015-03-23 2016-09-29 The University Of Melbourne Treatment of respiratory diseases
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
JP6781829B2 (ja) 2016-09-19 2020-11-04 メキシケム フロー エセ・ア・デ・セ・ヴェ 医薬組成物
RU2691110C2 (ru) * 2017-11-20 2019-06-11 Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения
AU2019374731B2 (en) 2018-11-07 2025-08-21 Tianli Biotech Pty Ltd Compounds and compositions for the treatment of respiratory diseases
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
PH12022551243A1 (en) 2019-12-02 2023-09-11 Chiesi Farm Spa Stainles steel can for pressurised metered dose inhalers
US12673065B2 (en) 2020-09-02 2026-07-07 Kuwait University Anti-inflammatory composition and method of treatment
CN120360953B (zh) * 2025-06-24 2025-09-05 成都第一制药有限公司 一种用于copd治疗的莨菪烷类生物碱组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315852A (zh) * 1998-08-04 2001-10-03 杰格研究股份公司 药用气溶胶制剂
CN1326341A (zh) * 1998-11-13 2001-12-12 杰格研究股份公司 用于吸入给药的干粉
CN1422154A (zh) * 2000-04-07 2003-06-04 阿拉凯斯有限公司 呼吸系统疾病的治疗
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
WO2003086399A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittel enthaltend steroide und ein neues anticholinergikum

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
EP0932401A1 (en) * 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6402285B1 (en) 1998-05-29 2002-06-11 Citizen Watch Co., Ltd. Method of subjecting ink jet printer to preuse treatment
US6086914A (en) 1999-03-12 2000-07-11 Weinstein; Robert E. Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6203779B1 (en) * 1999-03-19 2001-03-20 Charlie Ricci Methods for treating endoleaks during endovascular repair of abdominal aortic aneurysms
US20040002548A1 (en) 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE19961300A1 (de) 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009584D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
DE10062712A1 (de) 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2002096423A2 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
PA8546001A1 (es) 2001-05-25 2003-12-30 Pfizer Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
US7258118B2 (en) * 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
CA2478974C (en) * 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
AU2003272450A1 (en) 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
EP1610788A1 (en) 2003-03-28 2006-01-04 ALTANA Pharma AG Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PT1610787E (pt) 2003-03-28 2008-04-23 Nycomed Gmbh Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
US20060155491A1 (en) * 2003-07-11 2006-07-13 Peter Bode Frequency determination
CA2550841C (en) 2004-02-06 2012-10-02 Meda Pharma Gmbh & Co. Kg Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases
JP2007524698A (ja) 2004-02-27 2007-08-30 アルタナ　ファルマ　アクチエンゲゼルシャフト シクレソニドとグリコピロニウムとの組合せ物
PL1971369T3 (pl) 2005-12-21 2010-01-29 Meda Pharma Gmbh & Co Kg Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315852A (zh) * 1998-08-04 2001-10-03 杰格研究股份公司 药用气溶胶制剂
CN1326341A (zh) * 1998-11-13 2001-12-12 杰格研究股份公司 用于吸入给药的干粉
CN1422154A (zh) * 2000-04-07 2003-06-04 阿拉凯斯有限公司 呼吸系统疾病的治疗
CN1422620A (zh) * 2001-12-07 2003-06-11 中国人民解放军总装备部后勤部军事医学研究所 治疗氮氧化物中毒的气雾剂及其用途和制备方法
WO2003086399A1 (de) * 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittel enthaltend steroide und ein neues anticholinergikum

Also Published As

Publication number Publication date
DK1713473T3 (da) 2013-06-17
RU2440813C2 (ru) 2012-01-27
SI1713473T1 (sl) 2013-06-28
NO336882B1 (no) 2015-11-23
EP1713473A1 (en) 2006-10-25
RU2006132038A (ru) 2008-03-20
PL1713473T3 (pl) 2013-08-30
CA2551780C (en) 2013-02-26
WO2005074918A1 (en) 2005-08-18
AU2005210085A1 (en) 2005-08-18
HRP20130460T1 (hr) 2013-06-30
NO20063879L (no) 2006-11-01
PT1713473E (pt) 2013-05-13
US10537550B2 (en) 2020-01-21
CA2551780A1 (en) 2005-08-18
US20080300226A1 (en) 2008-12-04
EP1713473B1 (en) 2013-03-13
CN1913883A (zh) 2007-02-14
JP4819699B2 (ja) 2011-11-24
HK1098356A1 (zh) 2007-07-20
AU2005210085B2 (en) 2010-06-24
JP2007520508A (ja) 2007-07-26
ES2413011T3 (es) 2013-07-15
US20050175548A1 (en) 2005-08-11
NZ548300A (en) 2010-04-30

Similar Documents

Publication Publication Date Title
JP4819699B2 (ja) 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤
WO2000009127A1 (en) Remedies for multiple sclerosis
US20110034480A1 (en) Compositions comprising cetirizine and a non beta-2-adrenoreceptor agonist, a beta-2-adrenoreceptor agonist or an anti-inflammatory and the use thereof for the treatment of respiratory disorders
US20140329782A1 (en) Combined therapeutic agent
Hsieh et al. Comparative efficacy and tolerability of beclomethasone/formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients
US20220218672A1 (en) Thromboxane Receptor Antagonists in AERD/Asthma
WO2009032955A1 (en) Dheas inhalation compositions
HK1098356B (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
MXPA06008938A (en) The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
Bayoumi-Ali et al. Drugs That Act on the Respiratory Tract
RU2855994C2 (ru) Сложные эфиры монтелукаста и фармацевтические композиции, содержащие указанные соединения
Dodwell et al. Respiratory system: applied pharmacology
Pizzichini et al. Current role of anticholinergic drugs in the treatment of asthma
HK40066392A (en) Thromboxane receptor antagonists in aerd/asthma
CN118043051A (zh) 用于治疗或预防抗宿主病的吡咯并六元杂芳物
CN117180235A (zh) 一种无定型雷芬那辛吸入制剂
Saul et al. Respiratory system: applied pharmacology
Veeren Bronchial Smooth Muscle Agents
Buhl et al. Symptom-guided adjustable dosing asthma therapy with budesonide and formoterol in a single inhaler—The ATACO study
Basavaraj A Prospective, Randomised, Placebo Controlled, Double Blinded Comparative Study of Ramosetron Hydrochloride 0.3 mg and Dexamethasone 8mg Versus Ondansetron Hydrochloride 4mg and Dexamethasone 8mg in Prevention of Post Operative Nausea and Vomiting, in Patients Undergoing Gynaecological Surgeries Under Spinal Anaesthesia
WO2017201003A1 (en) Materials and methods for treating chronic cough

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098356

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098356

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091216

Termination date: 20220124

CF01 Termination of patent right due to non-payment of annual fee